LINC00511 influences cellular proliferation through cyclin-dependent kinases in papillary thyroid carcinoma
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (2) , 450-459
Abstract
Background: Proverbially, the incidence rate of papillary thyroid carcinoma (PTC) has increased year by year. Many long noncoding RNAs (lncRNAs) have been discovered having a relationship with tumor genesis tightly recently. Thanks to the previous researches, we found long intergenic noncoding RNA 00511 (LINC00511) is overexpressed and acts as an oncogene in non-small-cell lung cancer and breast cancer. However, the biological role and function of LINC00511 are still unclear in PTC.Keywords
This publication has 37 references indexed in Scilit:
- Long noncoding RNAs and the genetics of cancerBritish Journal of Cancer, 2013
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesJournal of Translational Medicine, 2013
- The CDK inhibitors in cancer research and therapyJournal of Cancer Research and Clinical Oncology, 2011
- Long Noncoding RNAs with Enhancer-like Function in Human CellsCell, 2010
- Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005Cancer, 2009
- Biomarkers for epithelial-mesenchymal transitionsJournal of Clinical Investigation, 2009
- Evolution and Functions of Long Noncoding RNAsCell, 2009
- Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrestInternational Journal of Cancer, 2007
- Clinically significant prognostic factors for differentiated thyroid carcinomaCancer, 2005
- Mammalian cyclin-dependent kinasesTrends in Biochemical Sciences, 2005